Multiple primer group and kit for identifying mycobacteria and drug-resistant sites based on multiple PCR (Polymerase Chain Reaction) and high-throughput sequencing and application
Through multiple PCR and high-throughput sequencing technology, multiple primer groups targeting mycobacterium were designed, and the library was built with fragmented enzymes, which solved the problem that the existing technology could not simultaneously identify Mycobacterium tuberculosis and non-tuberculosis mycobacterium tuberculosis and detect drug resistance sites. The problem of the problem has achieved rapid and accurate detection results and provided a scientific basis for clinical diagnosis.
Patent Information
- Application Number
- CN202411298390.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-18
- Publication Date
- 2024-11-08
AI Technical Summary
The existing mycobacterial detection methods cannot efficiently identify Mycobacterium tuberculosis and non-tuberculosis at the same time, and cannot detect multiple drug-resistant sites, resulting in challenges in clinical diagnosis and treatment.
Multiple PCR and high-throughput sequencing technology are used to design multiple primer groups targeting M. tuberculosis and non-M. tuberculosis specific genes and drug-resistant gene loci. Multiple PCR amplification and fragmentation enzyme library are built, and high-quality Throughput sequencing technology for detection.
It has achieved rapid and accurate identification of a variety of mycobacterium and its drug-resistant sites, provided comprehensive and accurate detection results, shortened detection time, simplified operational steps, and was suitable for clinical diagnosis and public health monitoring.
Smart Images

Figure CN118910301A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a multiplex primer set, a kit and an application thereof for identifying mycobacteria and drug resistance sites based on multiplex PCR and high-throughput sequencing technology. Background Art
[0002] Mycobacteria are important pathogens that cause a variety of human and animal diseases, among which Mycobacterium tuberculosis complex (MTBC) is the main pathogen that causes tuberculosis (TB). Tuberculosis is a serious infectious disease that causes millions of infections and deaths worldwide each year. Nontuberculous mycobacteria (NTM) are also an important class of pathogens that often cause lung, skin and soft tissue infections. Due to its wide variety and wide ecological distribution, the clinical diagnosis and treatment of NTM infection face great challenges.
[0003] Existing mycobacterium detection methods mainly include traditional bacterial culture, microscopy and molecular biology methods. Bacterial culture is the gold standard for mycobacterium detection, but its operation is complicated and time-consuming, and it usually takes weeks or even months to obtain results. Although microscopy is rapid, its sensitivity and specificity are low, and it cannot distinguish between different types of mycobacteria. Molecular biological methods, such as PCR and gene chip technology, can provide highly sensitive and specific detection results in a shorter time, but there are still some limitations. For example, a single PCR test cannot identify multiple mycobacteria at the same time and cannot provide information on drug resistance sites.
[0004] With the development of high-throughput sequencing technology, genomic and transcriptomic research has been greatly promoted. High-throughput sequencing technology can perform deep sequencing of a large number of DNA samples in a short period of time, thereby providing comprehensive genomic information. This provides new possibilities for the identification and drug resistance detection of mycobacteria.
[0005] CN 117701741 A discloses a primer set for identifying Mycobacterium tuberculosis complex and non-tuberculous mycobacteria and its application. The patent collects and analyzes the identification genes of Mycobacterium tuberculosis complex and non-tuberculous mycobacteria from the database, designs specific primers for the identification genes, combines multiplex PCR technology and targeted high-throughput sequencing technology, improves the detection sensitivity by super-multiplex PCR amplification and enrichment of the target, and improves the detection specificity based on the sequence reading of the gene sequencing platform, thereby achieving accurate and sensitive identification of mycobacteria. However, the patent can only identify Mycobacterium tuberculosis complex and non-tuberculous mycobacteria, and cannot identify drug-resistant sites.
[0006] CN 112921107A discloses a method for detecting heterogeneous drug resistance of Mycobacterium tuberculosis, which comprises using primer mixture 1 and primer mixture 2 to perform multiple PCR amplification on DNA of Mycobacterium tuberculosis, respectively, to obtain multiple PCR amplification product 1 and multiple PCR amplification product 2; heterogeneous drug resistance of Mycobacterium tuberculosis can be detected. However, the drug resistance gene sites of Mycobacterium tuberculosis detected in this patent are limited, and Mycobacterium tuberculosis and non-tuberculous mycobacteria cannot be identified.
[0007] Therefore, it is necessary to further efficiently integrate multiplex PCR and high-throughput sequencing technologies to develop a method that can simultaneously identify Mycobacterium tuberculosis and non-tuberculous mycobacteria and detect multiple resistance sites at the same time, so as to quickly and accurately identify mycobacterial species and their resistance sites, providing a scientific basis for clinical diagnosis and treatment. Summary of the invention
[0008] The object of the present invention is to provide a method and kit for mycobacterium identification and drug resistance site detection based on multiplex PCR and high-throughput sequencing technology. The method designs primers for specific genes and common drug resistance gene sites of Mycobacterium tuberculosis and various non-tuberculous mycobacteria to amplify the target DNA sequence by multiplex PCR. Then, the PCR product is fragmented by using a fragmentase, and a library is constructed by a fragmentase library construction method, and finally the library construction product is sequenced and analyzed by using a high-throughput sequencing technology.
[0009] The technical solution adopted by the present invention is:
[0010] A multiplex primer set for identifying mycobacteria and drug resistance sites based on multiplex PCR and high-throughput sequencing, wherein the sequences of the multiplex primer set are shown in SEQ NO 1 to SEQ NO 144.
[0011] The multiple primer set includes primers for the following target genes: Mycobacterium tuberculosis specific genes, non-tuberculous mycobacterium specific genes, and drug resistance gene sites.
[0012] The present invention also provides a kit for identifying mycobacteria and drug-resistant sites based on multiplex PCR and high-throughput sequencing. The kit comprises the multiplex primer set, and the sequence of the multiplex primer set is shown in SEQ NO 1 to SEQ NO 144.
[0013] The kit of the present invention may also include multiplex PCR reaction reagents, library construction reagents, NGS library quantification reagents, library purification reagents, and related reagents required for high-throughput sequencing, and may further include reagents and tools for extracting and purifying template DNA as needed. Corresponding commercially available kits may be used.
[0014] The present invention also provides an application of the kit for identifying mycobacteria and drug-resistant sites based on multiplex PCR and high-throughput sequencing to detect and identify mycobacteria and drug-resistant sites.
[0015] The mycobacterium is one or more of the mycobacterium of Mycobacterium tuberculosis complex, Mycobacterium avium complex, Mycobacterium leprae, Mycobacterium simian complex, Mycobacterium ulcerans complex, and non-tuberculous mycobacteria, and is a mycobacterium pathogenic to humans, specifically one or more of the following mycobacteria: Mycobacterium tuberculosis, Mycobacterium canetti, Mycobacterium antelope, Mycobacterium mongoose, Mycobacterium avium, Mycobacterium Aarhus, Mycobacterium manten, Mycobacterium paracellulare, Mycobacterium intracellulare, Mycobacterium Columbia, Mycobacterium massa, Mycobacterium estuary du Rhône, Mycobacterium senilis, Mycobacterium timonei, Mycobacterium leprae, Mycobacterium simian, Mycobacterium montefio, Mycobacterium florence, Mycobacterium intermedius Mycobacterium avium, Mycobacterium palustris, Mycobacterium geneva, Mycobacterium intermedia, Mycobacterium europaeus, Mycobacterium magna, Mycobacterium heidelberg, Mycobacterium kubica, Mycobacterium lentiflorum, Mycobacterium parma, Mycobacterium parala, Mycobacterium suscurvifolia, Mycobacterium shiga, Mycobacterium trio, Mycobacterium parascrofulae, Mycobacterium sherry, Mycobacterium ulcerans, Mycobacterium marine, Mycobacterium levlande, Mycobacterium pseudoshotts, Mycobacterium shotts, Mycobacterium xinglin, Mycobacterium alse, Mycobacterium basel, Mycobacterium hidden, Mycobacterium paragordonii, Mycobacterium angelfish, Mycobacterium bohemianum, Mycobacterium outstanding, Mycobacterium paraseouli, Mycobacterium aquaticum, Mycobacterium portney Mycobacterium, Mycobacterium cooke, Mycobacterium paraterrestris, Mycobacterium asiaticum, Mycobacterium bourgera, Mycobacterium deceives, Mycobacterium paraffinum, Mycobacterium attenuate, Mycobacterium brande, Mycobacterium dioxane-phagocytosis, Mycobacterium lehmannii, Mycobacterium fraga, Mycobacterium gross, Mycobacterium swiss, Mycobacterium new, Mycobacterium Frederiksberg, Mycobacterium haemophilum, Mycobacterium innocuum, Mycobacterium masse of Numidia, Mycobacterium gastricis, Mycobacterium black Kerschow, Mycobacterium kansasii, Mycobacterium ostraviae, Mycobacterium gordonii, Mycobacterium lake, Mycobacterium ke yoga, Mycobacterium palau, Mycobacterium malmo, Mycobacterium neglectum, Mycobacterium persianum, Mycobacterium niemehdn, Mycobacterium nebraska, Mycobacterium neuyi Mycobacterium manni, Mycobacterium breast, Mycobacterium pseudokansasii, Mycobacterium schreiberi, Mycobacterium surga, Mycobacterium leprae, Mycobacterium root masse, Mycobacterium shinjuku, Mycobacterium talmon, Mycobacterium sea dragon, Mycobacterium ryadi, Mycobacterium mimicum, Mycobacterium earth masse, Mycobacterium toad, Mycobacterium scrofula, Mycobacterium sponge, Mycobacterium thirburgi, Mycobacterium adjacent, Mycobacterium seoul, Mycobacterium são paulo (Mycobacterium são paulo), Mycobacterium abscessus (Mycobacterium abscessus), Mycobacterium franklini (Mycobacterium franklini), Mycobacterium salmoniphilum (Mycobacterium salmoniphilum), Mycobacterium tortoise (Mycobacterium tortoise), Mycobacterium immunogenum (Mycobacterium immunogenum),Mycobacterium koreanum (korean mycobacterium), Mycobacterium achromogenes (achromogenes), Mycobacterium acidophilum, Mycobacterium aropus (Arop mycobacterium), Mycobacterium algierse, Mycobacterium terrestris (terrestris), Mycobacterium algeriensis (Algerian mycobacterium), Mycobacterium virginianum, Mycobacterium beari (Beari mycobacterium), Mycobacterium minnesota (Minnesota mycobacterium), Mycobacterium engebeck (Ingbeck mycobacterium), Mycobacterium irish (Irish mycobacterium), Mycobacterium lombardi (Lombard mycobacterium), Mycolicibacter heraklionensis, Mycolicibacter senuensis, Aichi Mycolic acid rod-shaped bacteria (Aichi Mycobacterium), field Mycolic acid rod-shaped bacteria (field Mycobacterium), river channel Mycolic acid rod-shaped bacteria (river channel Mycobacterium), Anyang Mycolic acid rod-shaped bacteria (Anyang Mycobacterium), Good Mycolic acid rod-shaped bacteria, Arab Mycolic acid rod-shaped bacteria (Arab Mycobacterium), Bai Xiangning Mycolic acid rod-shaped bacteria, fast-growing yellow Mycolic acid rod-shaped bacteria (fast-growing yellow Mycobacterium), Hessen Mycolic acid rod-shaped bacteria (Hessen Mycobacterium), dearomatized Mycolic acid rod-shaped bacteria (dearomatized Mycobacterium ), Mycobacterium Bonnici (Mycobacterium Bonnici), Mycobacterium Chita (Mycobacterium Chita), Mycobacterium Seaside (Mycobacterium Seaside), Mycobacterium Aubagne (Mycobacterium Aubagne), Mycobacterium Brisbane (Mycobacterium Brisbane), Mycobacterium Chlorophenol (Mycobacterium Chlorophenol), Mycobacterium Lat (Mycobacterium Lat), Mycobacterium Aureum (Mycobacterium Aureum), Mycobacterium Winter (Mycobacterium Winter), Mycobacterium Chubu ( Mycobacterium truncatum), Mycobacterium insubriae (Mycobacterium insubriae), Mycobacterium southafricae (Mycobacterium southafricae), Mycobacterium canariensis (Mycobacterium canariensis), Mycobacterium designeri (Mycobacterium designeri), Mycobacterium trephinum (Mycobacterium trephinum), Mycobacterium bacteremiae (Mycobacterium bacteremiae), Mycobacterium cosmetica (Mycobacterium cosmetica), Mycobacterium flavosum (Mycobacterium flavosum), Mycobacterium glanders (Mycobacterium glanders Mycobacterium anthracis), Mycobacterium flavum (Mycobacterium flavum), Mycobacterium dillii, Mycobacterium fluorescens (Mycobacterium fluorescens), Mycobacterium iraniensis (Mycobacterium iraniensis), Mycobacterium chita (Mycobacterium chita), Mycolicibacterium doricum, Mycobacterium fortuitum (Mycobacterium fortuitum), Mycobacterium komani, Mycobacterium chlorophenol (Mycobacterium chlorophenol), Mycobacterium durolyum (Mycobacterium duroly),Mycobacterium cadisi (Mycobacterium cadisi), Mycobacterium dianchii, Mycobacterium chubu (Mycobacterium chubu), Mycobacterium elephanti (Mycobacterium elephanti), Mycobacterium leucodermi (Mycobacterium leucodermi), Mycobacterium houstonii (Mycobacterium houstonii), Mycobacterium designeri (Mycobacterium designeri), Mycobacterium koblenzii (Mycobacterium koblenzii), Mycobacterium luteum (Mycobacterium luteum), Mycobacterium hippocampi (Mycobacterium hippocampi), Mycolicibacterium holsaticum, Mycobacterium van Barenii (Mycobacterium van Barenii), Mycobacterium lutetiae (Mycobacterium lutetiae), Mycobacterium muciniphilum (Mycobacterium muciniphilum), Mycobacterium parafortuitum (Mycobacterium parafortuitum), Mycobacterium chlorovinyl, Mycobacterium madagascarii (Mycobacterium madagascar), Mycobacterium wallii (Mycobacterium wallii), Mycobacterium exogenum (Mycobacterium exogenum), Mycobacterium woundii, Mycobacterium margaritum Mycobacterium margaritense, Mycobacterium neogoldenum (Mycobacterium neogoldenum), Mycobacterium phlei (Mycobacterium phlei), Mycobacterium licheniformis (Mycobacterium licheniformis), Mycobacterium malmesburyiformis (Mycobacterium malmesburyiformis), Mycobacterium new orleans (Mycobacterium new orleans), Mycobacterium forscia (Mycobacterium forscia), Mycobacterium stelleri, Mycobacterium mengxianglii, Mycobacterium snowiformis, Mycobacterium multiporum (Mycobacterium sponge) , heat-resistant mycobacterium acid rods (heat-resistant mycobacterium), Murray black mycobacterium acid rods (Murray black mycobacterium), Newcastle mycobacterium acid rods (Newcastle mycobacterium), cold-resistant mycobacterium acid rods (cold-resistant mycobacterium), pitcher grass mycobacterium acid rods (piter grass mycobacterium), Morioka mycobacterium acid rods (Morioka mycobacterium), Aubu mycobacterium acid rods (Aubu mycobacterium), dust mycobacterium acid rods (dust mycobacterium), sediment mycobacterium acid rods (sediment mycobacterium), Rhodesiella mycobacterium acid rods (Mycobacterium rhodesiense), Mycobacterium septicum (Mycobacterium septicum), Mycobacterium donghaiensis (Mycobacterium donghaiensis), Mycobacterium senegalensis, Mycobacterium rubrum, Mycobacterium sete (Mycobacterium sete), Mycobacterium tuscanum (Mycobacterium tuscanum), Mycobacterium wolinskii (Mycobacterium wolinskii), Mycobacterium ferrugineum (Mycobacterium ferrugineum), Mycobacterium smegmatis (Mycobacterium smegmatis), Mycobacterium bovis (Mycobacterium bovis).
[0016] The drug resistance sites include one or more of the following drug resistance gene mutations:
[0017] (I) Drug resistance genes of Mycobacterium tuberculosis: ahpC, ddn, eis, embA, embB, ethA, gidB, gyrA, gyrB, inhA, katG, pncA, rplC, rpoB, rpsL, rv0678, tlyA, rrl, rrs;
[0018] (ii) Nontuberculous mycobacterial resistance genes: rrl, rrs, erm41;
[0019] (III) Isoniazid drug metabolism gene NAT2.
[0020] The present invention also provides a method for identifying mycobacteria and drug-resistant sites based on multiplex PCR and high-throughput sequencing, wherein the method uses the kit for identifying mycobacteria and drug-resistant sites based on multiplex PCR and high-throughput sequencing, and the method comprises the following steps:
[0021] (1) extracting nucleic acid from the sample to be tested;
[0022] (2) using a multiple primer set to perform a multiple PCR amplification reaction on the nucleic acid extracted from the test sample to amplify the target nucleic acid sequence;
[0023] (3) The multiplex PCR reaction products are used to construct a library, perform high-throughput sequencing, and perform bioinformatics analysis on the sequencing results to obtain the mycobacterium identification results and drug resistance site detection results in the test samples.
[0024] In the step (3), constructing the library generally includes nucleic acid fragmentation, end repair and A addition, adapter ligation, and final purification to obtain the library.
[0025] Nucleic acid fragmentation treatment generally uses a fragmentase to fragment the multiplex PCR reaction products.
[0026] The adapter connection generally uses a ligase to connect the specific adapter sequence to the fragmented, end-repaired, and A-added product.
[0027] The samples to be tested can be various clinical samples or collected and cultured strain samples. Clinical samples include sputum, alveolar lavage fluid, pleural effusion, puncture tissue, etc.
[0028] In the method of the present invention, multiplex PCR technology is a method for simultaneously amplifying multiple target sequences in the same reaction system, which has the advantages of high efficiency, rapidity and low cost. Fragmentation enzyme library construction technology can efficiently fragment PCR products to generate fragments suitable for high-throughput sequencing, and through specific adapter connection, realize the rapid construction of high-throughput sequencing library. High-throughput sequencing technology can perform deep sequencing of a large number of DNA fragments in a short time, providing comprehensive and accurate genomic information.
[0029] In the step (1), the sample to be tested may be pre-treated before nucleic acid is extracted, and the pre-treatment includes liquefaction treatment and physical shaking.
[0030] Liquefaction can reduce the viscosity of the sample, making it easier to handle and protecting the nucleic acids therein from oxidative damage; liquefaction reagents usually contain enzymes or other chemicals that can break down mucins and cell fragments, such as guanidine hydrochloride, cysteine, dithiothreitol, sodium hydroxide, etc.
[0031] Physical oscillation can break the cell walls of cells in the sample, allowing the nucleic acid of pathogenic microorganisms to be better released and improving the detection rate of pathogens. It is easy to operate and pollution-free.
[0032] Physical vibration can be achieved by homogenization or ultrasound.
[0033] In the step (2), the sample DNA to be tested is preferably used as the template DNA, and a multiplex PCR reaction system is prepared with a multiplex primer set to perform a multiplex PCR amplification reaction;
[0034] The multiplex PCR reaction system comprises multiple primer sets, a dNTP mixture, a PCR buffer, a thermostable DNA polymerase and a template DNA.
[0035] In the step of constructing the library, the present invention adopts a method of efficiently fragmenting the PCR product using a fragmentase, which is simple to operate, low in cost and does not damage DNA. In addition, a PCR-free method is used for library construction, and PCR amplification is not performed after the adapter connection step, which can avoid amplification errors and aerosol contamination introduced by PCR preference, reduce PCR bias and GC bias, better retain the integrity of the fragment length, and improve sequencing accuracy.
[0036] In the step (3), the library construction system includes a fragmentation enzyme, a fragmentation reaction buffer, a ligase required for fragmentation enzyme library construction and its reaction buffer, and a library construction adapter.
[0037] Compared with the prior art, the technical solution of the present invention has the following advantages:
[0038] 1) The multiple primer set involved in the present invention includes primers for important genes of mycobacteria, such as strain identification genes of Mycobacterium tuberculosis and non-tuberculous mycobacteria, and drug resistance genes of Mycobacterium tuberculosis and non-tuberculous mycobacteria, which can specifically bind to specific gene segments of mycobacteria. Each non-tuberculous mycobacterium strain identification primer takes into account the diversity of non-tuberculous mycobacteria when designing to ensure that a variety of non-tuberculous mycobacteria can be covered. Each drug resistance gene primer takes into account the diversity of drug resistance sites when designing to ensure that multiple sites of drug resistance genes can be covered. The present invention can identify up to 207 species of mycobacteria, detect multiple sites of 21 drug resistance genes, and the test results are comprehensive and accurate.
[0039] 2) High sensitivity and high specificity: Through multiplex PCR and high-throughput sequencing technology, it can accurately detect and identify multiple mycobacteria and their resistance sites at the same time, providing comprehensive and accurate detection results.
[0040] 3) Rapid detection: Compared with traditional bacterial culture methods, this method greatly shortens the detection time and usually obtains results within a few days.
[0041] 4) Easy operation: The combination of multiplex PCR, fragmentation enzyme treatment and PCR-free library construction technology simplifies the operation steps and reduces the complexity of the experiment.
[0042] 5) Wide application: This method and kit can be widely used in clinical diagnosis, public health monitoring and scientific research, etc., which will help improve the detection efficiency of mycobacterial infection and the level of drug resistance monitoring, and provide a scientific basis for the prevention, control and treatment of mycobacterial infection. It has important application value and broad market prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 The figure is a flow chart of the experimental steps of the method for identifying mycobacteria and drug resistance sites based on multiplex PCR and high-throughput sequencing of the present invention. DETAILED DESCRIPTION
[0044] For ease of understanding, the technical method provided by the present invention is elaborated and described in detail below in conjunction with specific embodiments and accompanying drawings, and the embodiments are only a part of embodiments of the present invention and are not limited to all embodiments of the present invention. The reagent components used in the following examples are commercially available unless otherwise specified. The modifications or changes based on the present invention by professionals in the field, the modes of these equivalent modifications also fall within the scope of the claims described in the claims of the present invention.
[0045] Example 1: High-throughput sequencing of 13 respiratory samples
[0046] 1. Experimental Methods
[0047] 1.1 Sample pretreatment
[0048] Respiratory samples: Add 1 mL of liquefaction reagent (containing 0.96 g / mL guanidine hydrochloride and 0.25 g / mL cysteine) to 1 mL to 4 mL of sample, vortex and vibrate to mix for 2 to 5 minutes until the sample is fully liquefied. After liquefaction, perform pre-treatment such as homogenization before subsequent extraction operations.
[0049] Other samples: The sample test volume is 1 mL. If the sample to be tested is less than 1 mL, PBS / normal saline / nuclease-free water can be used to make it up to 1 mL; an ultrasonic device or homogenizer can be used for pretreatment according to the corresponding instructions.
[0050] 1.2 Nucleic Acid Extraction The nucleic acids of the 13 samples were extracted using the MD049T Nucleic Acid Extraction Kit (magnetic bead method), and then the DNA concentration of the nucleic acids was determined using the Qubit fluorometer and its accompanying Qubit DNA detection kit.
[0051] 1.3 Multiplex Amplification
[0052] 1.3.1 Preparation of multiple amplification system: (should be completed in the laboratory pre-PCR area, reagents should be prepared in the reagent preparation room, and templates should be added in the specimen preparation area.)
[0053] 1.3.1.1 First, thaw the reagents in the tuberculosis and non-tuberculosis mycobacterium resistance site multiplex amplification kit on ice and mix them thoroughly (except enzymes, which are collected by centrifugation to the bottom of the tube and cannot be vortexed). According to the number of specimens and the number of quality controls (NC-A), prepare 0.2ml nuclease-free eight-tube strips and mark them, and add each component to the tube according to the table below. When there are many specimens, you can first prepare the premix according to the quantity and then dispense it, and then add nucleic acids separately. When preparing the reaction solution, put the reagents on ice. Please use new (uncontaminated filter) pipette tips, centrifuge tubes, etc. for the preparation and dispensing of the reaction solution. Please avoid cross-contamination of specimens when operating in each reaction well.
[0054]
[0055] 2× buffer and multiplex DNA amplification enzyme were purchased from Novagen, catalog number PM202-C6.
[0056] The main components of 2× buffer are Heat-labile UDG, dNTPs (dATP, dGTP, dCTP, dTTP, dUTP), Mg 2+ 、KCl、(NH4) 2 SO 4 ,glycerin.
[0057] The main components of the multiplex DNA amplification enzyme are Multiplex DNA Polymerase (Taq enzyme) and Storage Buffer (main components: 50% glycerol, Tris-HCl, Tween 20, etc.).
[0058] The primer mix includes primers with sequences shown in SEQ ID NOs 1 to 144 shown in the following table, and the concentration of each primer is 10 μM.
[0059]
[0060]
[0061]
[0062]
[0063] 1.3.1.2 In addition to the specimen, a synchronously extracted NC4 nucleic acid (to control the contamination introduced by the extraction process, marked as NC-A) and a separate NF H2O as a negative control should be set up each time. The volume of nucleic acid added to the above quality control is based on the specimen, that is, 5μL per reaction well.
[0064] 1.3.2 Amplification program settings
[0065] Set the program according to the table below. The temperature of the hot cover is 105°C. After the reaction is completed, it needs to be cooled to 4°C before it can be taken out.
[0066]
[0067] 1.4 Library construction (PCR product tubes must be opened in the post-PCR area! Opening must be done in a biosafety cabinet.) Use the metagenomic DNA library construction kit (reversible terminal termination sequencing method), item number MD001P. 1.4.1 Amplification product: After the PCR reaction is completed, remove the reaction tube and place it on an ice box for 5-10 minutes.
[0068] Open the lid in a biological safety cabinet.
[0069]
Note
[0070] 1.4.2 DNA fragmentation
[0071] 1.4.2.1 Thaw the reagents on ice and mix thoroughly. Centrifuge the enzyme instantaneously without vortexing.
[0072] 1.4.2.2 Prepare 0.2ml eight-tube strips and place them on ice and mark them. Add reagents to the tubes in sequence according to the table below, vortex for 5 seconds, mix well, and centrifuge for 5 seconds. Make sure there are no bubbles. When there are many specimens, you can prepare the premix according to the quantity and then dispense it, and then add the corresponding amplification product.
[0073]
[0074]
[0075] The main components of the fragment filling enzyme are non-specific nuclease, T7 endonuclease mutant, and DNA filling enzyme.
[0076] The main components of the fragmentation buffer are 50 mM sodium chloride, 10 mM tris-hydrochloric acid (Tris-HCl), 10 mM magnesium chloride, 1 mM dithiothreitol (DTT), and 4 μM dNTP.
[0077] The main components of the balancing buffer are 10 mM Tris-HCl and 3.2 mM dithiothreitol (DTT).
[0078] 1.4.2.3 Place the PCR tube containing the above reaction solution into the PCR instrument, set the heating cover temperature to 100℃, and perform the reaction according to the following procedure.
[0079]
[0080] 1.4.2.4 After the program is completed, remove the PCR reaction tube from the PCR instrument and place it on ice.
[0081] 1.4.3 Connector connection
[0082] 1.4.3.1 Take 5 μL of ligase and add it to each PCR tube in step 1.4.2.4.
[0083] 1.4.3.2 Add 30 μL of connector to each PCR tube, taking care to avoid cross contamination, and cover the eight-tube strip cap.
[0084] 1.4.3.3 Vortex the mixture for 5 seconds, mix thoroughly, and centrifuge briefly.
[0085] 1.4.3.4 Place the PCR tube in the PCR instrument, set the cover temperature to 100°C, and perform the reaction according to the following procedure. After the reaction is completed, take out the tube and perform library purification.
[0086]
[0087] 1.5 Library purification
[0088] Library purification using a nucleic acid purification kit (magnetic beads method):
[0089] 1.5.1 Equilibrate the purified magnetic beads at room temperature for 30 min.
[0090] 1.5.2 Vortex to fully suspend the magnetic beads, take 40 μL of purified magnetic beads, add them to the library construction product, and vortex to mix thoroughly.
[0091] 1.5.3 Incubate at room temperature for 5 minutes to allow the DNA to fully bind to the magnetic beads, and then place the reaction tube on the magnetic rack. After the solution is clear (about 5 minutes), carefully aspirate and discard the supernatant with a pipette.
[0092] 1.5.4 The PCR tube is always placed on the magnetic rack, and 200 μL of purification cleaning solution (0.02%
[0093] ProClin300), let it stand for 30 seconds, and carefully discard the supernatant with a pipette.
[0094] (Note: Do not blow away the magnetic beads when adding purification cleaning solution to rinse the magnetic beads; after washing, use a pipette to absorb as much residual cleaning solution as possible.)
[0095] 1.5.5 Repeat step 1.5.4 once. Use a 10 μL pipette tip to remove all remaining wash solution.
[0096] 1.5.6 The reaction tube is always placed on the magnetic rack and left to air-dry at room temperature with the lid open for 3 to 5 minutes.
[0097] (Note: The dry mark indicates that the beads are in a matte state. Do not overdry the beads, as this will affect the yield. If there is any residual purification solution, it will affect the subsequent library quantification.)
[0098] 1.5.7 Add 42 μL of purification eluent (10 mM Tris(OH)2M, pH 8.0-8.2; 0.05% Tween-20) to the tube, oscillate to mix and suspend the magnetic beads, let stand at room temperature for 5 min, centrifuge briefly, and place the reaction tube on a magnetic rack for 3-5 min. After the solution is clarified, transfer 40 μL of the supernatant to a new PCR tube. This is the resulting library, which can be used for subsequent experiments.
[0099] 1.6 Library quantification
[0100] The library was diluted 20 times (4ul stock solution + 76μL purified eluate), and the library concentration was quantified using the NGS library quantification kit (probe method) catalog number MD057, strictly following the instructions of the kit.
[0101] 1.7 Sequencing reaction
[0102] Illumina NextSeq500 and sequencing reaction universal kit (reversible terminal termination sequencing method), catalog number MD004, were used for DNA sequence detection, and sequencing was performed strictly in accordance with the sequencing kit and instrument instructions. The sequencing method was set as follows:
[0103]
[0104] 2. Results Analysis
[0105] The sequencing data of each sample are detailed in the table below. The results of mycobacterium identification and drug-resistant mutation detection are consistent with the expected results of the samples.
[0106]
[0107] When the following 10 samples were tested using this method, the fluorescence quantitative PCR method was used for verification simultaneously. It can be seen that this method can stably detect when CT is around 38:
[0108] Serial number Internal encoding This method Tuberculosis PCR Validation 1 N01C24190203L Tuberculosis positive CT value 36.11 2 N01C24160300L Tuberculosis positive CT value 38.46 3 N01C24170253Z Tuberculosis positive CT value 38.71 4 N01C24150234L Tuberculosis positive CT value 38.1 5 N01C24160300L Tuberculosis positive CT value 38.4 6 N01C24180106L Tuberculosis positive CT value 35.97 7 N01C24150428L Tuberculosis positive CT value 34.81 8 N01C24190090L Tuberculosis positive CT value 37.27 9 N01C24150150L Tuberculosis positive CT value 37.01 10 N01C24210493N Tuberculosis positive CT value 35.16
[0109] The final concentration was 1×10 4 CFU / ml, 1×10 3 CFU / ml, 1×10 2 The national reference materials of tuberculosis single-cell drug-resistant bacteria of 1×10 CFU / ml and 1×10 CFU / ml were used to test the sensitivity (targeting three drug-resistant genes, repeated twice), and the detection limit performance of tuberculosis resistance site identification was obtained as shown in the following table:
[0110]
[0111]
[0112] The accuracy of drug resistance testing was verified using national reference materials, and the accuracy data was shown in the following table:
[0113]
[0114] The mycobacterium detection range is as follows:
[0115] The detection range of the four major complex groups of Mycobacterium / Mycobacterium leprae is as follows:
[0116]
[0117]
[0118] The detection range of other non-binding mycobacteria (NTM) is shown in the table below:
[0119]
[0120]
[0121]
Claims
1. A multiplex primer set for identifying mycobacteria and drug resistance sites based on multiplex PCR and high-throughput sequencing, characterized in that The sequences of the multiple primer sets are shown in SEQ NO 1 to SEQ NO 144:
2. A kit for identifying mycobacteria and drug resistance sites based on multiplex PCR and high-throughput sequencing, characterized in that The kit comprises the multiple primer set as claimed in claim 1, and the sequence of the multiple primer set is shown in SEQ NO 1 to SEQ NO 144.
3. Use of the kit for identifying mycobacteria and drug-resistant sites based on multiplex PCR and high-throughput sequencing as claimed in claim 2 to detect and identify mycobacteria and drug-resistant sites.
4. The use according to claim 3, characterized in that The mycobacterium is one or more of the following mycobacteria: Mycobacterium tuberculosis, Mycobacterium canetti, Mycobacterium antelope, Mycobacterium mongoose, Mycobacterium avium, Mycobacterium Aarhus, Mycobacterium manten, Mycobacterium paracellulare, Mycobacterium intracellulare, Mycobacterium Columbia, Mycobacterium Massa, Mycobacterium estuary du Rhône, Mycobacterium Thousands, Mycobacterium Timone, Mycobacterium leprae, Mycobacterium simianum, Mycobacterium Montefiore, Mycobacterium Florence, Mycobacterium intermedius, Mycobacterium avazikum, Mycobacterium palustris, Mycobacterium geneva, Mycobacterium intermedia, Mycobacterium europaeus, Mycobacterium macrocarpon, Mycobacterium Heidelberg, Mycobacterium Kubica, Mycobacterium lentiflavum, Mycobacterium Parma, Mycobacterium Parma, Mycobacterium spp. Mycobacterium la, Mycobacterium saskatchewan, Mycobacterium shiga, Mycobacterium trio, Mycobacterium parascrofulae, Mycobacterium sherry, Mycobacterium ulcerans, Mycobacterium marine, Mycobacterium liveland, Mycobacterium pseudoshotts, Mycobacterium shotts, Mycobacterium xinglin, Mycobacterium alse, Mycobacterium basel, Mycobacterium hidden, Mycobacterium paragordonii, Mycobacterium angelfish, Mycobacterium bohemianum, Mycobacterium outstanding, Mycobacterium paraseouli, Mycobacterium aquaticum, Mycobacterium portney, Mycobacterium cooke, Mycobacterium paraterrestris, Mycobacterium asiaticum, Mycobacterium bourgera, Mycobacterium deceive, Mycobacterium paraffinum, Mycobacterium attenuation, Mycobacterium brand, Mycobacterium dioxanephagum, Mycobacterium lymanii, Mycobacterium fraga Bacillus, Mycobacterium Gross, Mycobacterium Swiss, Mycobacterium New, Mycobacterium Frederiksberg, Mycobacterium Haemophilus, Mycobacterium Innocent, Mycobacterium Numidia-Massai, Mycobacterium Gastric, Mycobacterium Heckershaw, Mycobacterium Kansasii, Mycobacterium Ostravium, Mycobacterium Gordon, Mycobacterium Lake, Mycobacterium Kyogi, Mycobacterium Palau, Mycobacterium Malmo, Mycobacterium Neglected, Mycobacterium Persian, Mycobacterium Nijmegen, Mycobacterium Nebraska, Mycobacterium Neumann, Mycobacterium Mammary, Mycobacterium Pseudomonas Kansasii, Mycobacterium Schwarzeneggeri, Mycobacterium Surga, Mycobacterium Leprae Tumori, Mycobacterium Root-Massai, Mycobacterium Shinjuku, Mycobacterium Talmon, Mycobacterium Sea Dragon, Mycobacterium Riyadh, Mycobacterium simulans, Mycobacterium terrestris, Mycobacterium toad, Mycobacterium scrofula, Mycobacterium sponge, Mycobacterium thirburgi, Mycobacterium adjacent, Mycobacterium Seoul, Mycobacterium São Paulo, Mycobacterium abscessus, Mycobacterium Franklini, Mycobacterium salmoniphilum, Mycobacterium turtle, Mycobacterium immunogenum, Mycobacterium koreanum, Mycobacterium achromogenes, Mycobacterium acidophilus, Mycobacterium aropus, Mycobacterium Marseilles of Algiers, Mycobacterium terrestris, Mycobacterium Algeria, Mycobacterium Virginiana, Mycobacterium Kumamoto, Mycobacterium Minnesota, Mycobacterium Ingbeck, Mycobacterium Ireland, Mycobacterium Lombardy,Mycolicibacterheraklionensis, Mycolicibacter senuensis, Aichi mycolic acid rod-shaped bacteria, field mycolic acid rod-shaped bacteria, river channel mycolic acid rod-shaped bacteria, Anyang mycolic acid rod-shaped bacteria, Good mycolic acid rod-shaped bacteria, Arabian mycolic acid rod-shaped bacteria, Bai Xiangning mycolic acid rod-shaped bacteria, fast-growing yellow mycolic acid rod-shaped bacteria, Hessen mycolic acid rod-shaped bacteria, dearomatized mycolic acid rod-shaped bacteria, Bonick mycolic acid rod-shaped bacteria, Qiantian mycolic acid rod-shaped bacteria, seaside mycolic acid rod-shaped bacteria, Aubagne mycolic acid rod-shaped bacteria, Brisbane mycolic acid rod-shaped bacteria, chlorophenol mycolic acid rod-shaped bacteria, Rat mycolic acid rod-shaped bacteria, golden mycolic acid rod-shaped bacteria Mycolic acid bacilli, winter mycolic acid bacilli, Chubu mycolic acid bacilli, Insubria mycolic acid bacilli, South African mycolic acid bacilli, Canary Islands mycolic acid bacilli, designer mycolic acid bacilli, tricky mycolic acid bacilli, bacteremia mycolic acid bacilli, cosmetic mycolic acid bacilli, yellowish mycolic acid bacilli, glanders mycolic acid bacilli, fast-growing yellow mycolic acid bacilli, Di's mycobacterium, fluoranthene-eating mycolic acid bacilli, Iranian mycolic acid bacilli, Chida mycolic acid bacilli, Mycolicibacterium doricum, Mycobacterium fortuitum, Mycobacterium komanii, Mycobacterium chlorophenolicum, Mycobacterium duli, Mycobacterium caddisi, Mycobacterium dianchiensis, Mycobacterium chubu, Mycobacterium elephantum, Mycobacterium flavosum, Mycobacterium houstonianum, Mycobacterium koblenzii, Mycobacterium flavosum, Mycobacterium hippocampi, Mycolicibacterium holsaticum, van Baaren mycobacterium, lutetia mycobacterium, mucoid mycobacterium, parafortuitous mycobacterium, vinylchlorid mycobacterium, Madagascar mycobacterium, wall mycobacterium, alien mycobacterium, wound mycobacterium, margarite mycobacterium, new golden mycobacterium, grass mycobacterium, marl moss mycobacterium, Malmesbury mycobacterium, new orleans mycobacterium, forsia mycobacterium, wolfsbacterium , Meng Xiangli mycolic acid rod-shaped bacteria, snow-like mycolic acid rod-shaped bacteria, porous mycolic acid rod-shaped bacteria, heat-resistant mycolic acid rod-shaped bacteria, Murray black mycolic acid rod-shaped bacteria, Newcastle mycolic acid rod-shaped bacteria, cold-resistant mycolic acid rod-shaped bacteria, pitcher grass mycolic acid rod-shaped bacteria, Morioka mycolic acid rod-shaped bacteria, Aubu mycolic acid rod-shaped bacteria, dust mycolic acid rod-shaped bacteria, sediment mycolic acid rod-shaped bacteria, Rhodesian mycolic acid rod-shaped bacteria, septicemic mycolic acid rod-shaped bacteria, Donghai mycolic acid rod-shaped bacteria, Senegal mycobacterium, red mycobacterium, Sete mycolic acid rod-shaped bacteria, Tuscan mycolic acid rod-shaped bacteria,Mycobacterium wolinskii, Mycobacterium ferruginosa, Mycobacterium smegmatis, Mycobacterium bovis.
5. The use according to claim 3, characterized in that The drug resistance sites include one or more of the following drug resistance gene mutations: (I) Drug resistance genes of Mycobacterium tuberculosis: ahpC, ddn, eis, embA, embB, ethA, gidB, gyrA, gyrB, inhA, katG, pncA, rplC, rpoB, rpsL, rv0678, tlyA, rrl, rrs; (ii) Nontuberculous mycobacterial resistance genes: rrl, rrs, erm41; (III) Isoniazid drug metabolism gene NAT2.
6. A method for identifying mycobacteria and drug resistance sites based on multiplex PCR and high-throughput sequencing, the method using the kit for identifying mycobacteria and drug resistance sites based on multiplex PCR and high-throughput sequencing as claimed in claim 2, characterized in that: The method comprises the following steps: (1) extracting nucleic acid from the sample to be tested; (2) using a multiple primer set to perform a multiple PCR amplification reaction on the nucleic acid extracted from the sample to amplify the target nucleic acid sequence; (3) The multiplex PCR reaction products are used to construct a library, perform high-throughput sequencing, and perform bioinformatics analysis on the sequencing results to obtain the mycobacterium identification results and drug resistance site detection results in the test samples.
7. The method according to claim 6, characterized in that In the step (2), the nucleic acid extracted from the sample to be tested is used as a template DNA, and a multiplex PCR reaction system is prepared with a multiplex primer set to perform a multiplex PCR amplification reaction; The multiplex PCR reaction system comprises multiple primer sets, a dNTP mixture, a PCR buffer, a thermostable DNA polymerase and a template DNA.
8. The method according to claim 6, characterized in that In the step (3), constructing the library includes nucleic acid fragmentation, end repair and A addition, adapter ligation, and final purification to obtain the library.
9. The method according to claim 8, characterized in that In the step (3), a fragmentation enzyme is used to perform nucleic acid fragmentation treatment.
Citation Information
Cited By
Crocus sativus rhizosphere microorganism and application thereof
CN119391591A
Crocus rhizosphere microorganism and application thereof
CN119391591B
Primer group for detecting mutation site of human cytomegalovirus UL54 drug-resistant gene and application of primer group
CN121380447A
